CJC-1295 / Ipamorelin Peptide Research
CJC-1295 / Ipamorelin is a popular growth-hormone-axis protocol that combines a long-acting GHRH analog with a selective ghrelin-receptor agonist.
gh-axis peptide protocol
Clinical
research maturity
Overview
CJC-1295 / Ipamorelin is a popular growth-hormone-axis protocol that combines a long-acting GHRH analog with a selective ghrelin-receptor agonist. The pairing is intended to support endogenous GH release rather than directly replace growth hormone.
Related stacks
Apex Stack
Performance Stack
GH Optimization Stack
Mechanism
CJC-1295 aims to stimulate GHRH receptor signaling at the pituitary, while ipamorelin acts at the ghrelin receptor to augment pulsatile GH secretion. The combination is designed around complementary secretagogue pathways rather than direct GH replacement.
Clinical interest
Clinical interest focuses on body composition, recovery, GH-axis support, and hormone-optimization programs. It is often framed as an endogenous-stimulation strategy rather than a somatropin substitute.
Research summary
Evidence includes direct CJC-1295 endocrine studies, ipamorelin pituitary-testing literature, and broader reviews of GH secretagogues and GHRH analogs. The combination concept is biologically coherent, but modern long-term outcome trials on the pair are limited.
Safety considerations
Because the protocol manipulates the GH/IGF-1 axis, concerns include edema, glucose effects, headaches, and unmonitored IGF-1 elevation. Quality control and compounding variability are also relevant outside formal drug development.
Key information
Research stage
Clinical
Evidence rating
Moderate
Search intent
informational
Last review
Mar 13, 2026
Featured studies
(
6
)
Frequently asked questions
What is CJC-1295 / Ipamorelin used to study?
It is studied and discussed as a GH-axis secretagogue protocol intended to stimulate endogenous growth-hormone release through complementary GHRH and ghrelin-receptor pathways.
Is it the same as taking growth hormone?
No. Somatropin is direct recombinant human growth hormone, while CJC-1295 / Ipamorelin is an endogenous-stimulation approach that depends on pituitary responsiveness.